Full-Time
Tango Therapeutics
51-200 employees
Develops targeted cancer therapies using genetics
No salary listed
Junior, Mid
Boston, MA, USA
Upload your resume to see how it matches 8 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- Proficiency in Microsoft Office including Word, Outlook, Excel, and PowerPoint required
- Ability to learn how to troubleshoot Audio/Visual (A/V) issues in the office
- Must be ambitious, eager, a fast-learner, willing and able to perform in a fast-paced and dynamic, professional environment
- Excellent organizational skills with strong attention-to-detail with the ability to effectively multi-task are essential
- Demonstrated flexibility and professional maturity to readily understand priorities and anticipate needs
- Must be able to take initiative and follow through as well as maintain confidential information
- Strong written and verbal communication skills are essential
- Greet all visitors, answer phones; screen and direct calls as appropriate
- Register all incoming guests and manage guest reservation system in collaboration with the building security team
- Order and set up office lunches once a week; pick and set up lunches for all internal and external meetings
- Upkeep and stocking of the kitchen including ordering weekly groceries and happy hour items
- General office support, such as triaging questions, assisting with room booking and meeting scheduling ordering office supplies, and maintaining conference rooms
- Troubleshoot AV issues
- Assist with planning of events as needed
- New hire onboarding including providing an office overview to all new hires as well as maintaining office onboarding documents
- Serve as liaison between admin, IT, and Facilities teams; ensure updates are provided among teams as needed
- Assist with troubleshooting for issues related to the visitor check-in process, guest wifi, meeting room management in Outlook, etc.
- Coordinate with Facilities on year-end office shutdown
- Identify areas of improvement in office processes and assist with implementing solutions
- Create and maintain documentation for office systems
- Additional duties and responsibilities as requested
- 1-3 years of related administrative assistant experience preferred; no previous experience is required
- Bachelor’s degree preferred but not required
Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both leads to cell death. They primarily serve healthcare providers and pharmaceutical companies in the oncology market. Tango collaborates with larger pharmaceutical firms, like Gilead Sciences, to co-develop therapies, which helps them secure funding and speed up the development process. Their goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2017
Simplify's Take
What believers are saying
- Growing interest in synthetic lethality enhances Tango's innovative approach in oncology.
- Recent $80 million financing strengthens Tango's financial position for future developments.
- FDA clearance for TNG348 and TNG462 boosts Tango's clinical trial advancements.
What critics are saying
- Discontinuation of TNG348 due to liver toxicity may affect investor confidence.
- Reliance on partnerships for financial support poses risks if partnerships change.
- Intensifying competition in precision oncology could impact Tango's market share.
What makes Tango Therapeutics unique
- Tango leverages synthetic lethality to target cancer cells while sparing healthy ones.
- Their focus includes counteracting tumor suppressor gene loss and immune evasion.
- Strategic collaborations with pharma companies accelerate development and commercialization of therapies.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 1%BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that it will discontinue development of its TNG348 program. “Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial. While disappointing, we believe this is the right decision given the data at hand,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “We will focus resources and capital on our existing portfolio, particularly our PRMT5 program. We remain committed to and confident in our ability to deliver a comprehensive clinical update on TNG908 and TNG462 in the second half of this year.”
BOSTON--(BUSINESS WIRE)-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.“In 2023, we made meaningful progress developing precision oncology treatments and now have four ongoing phase 1/2 clinical trials. These treatments have the potential to reach people with a wide range of cancers, including those with MTAP-deleted solid tumors, STK11 loss-of-function mutations, BRCA 1/2 mutations and other DNA damage repair defects. To support the advancement of our broad clinical portfolio, we expanded our management team, adding members with expertise in regulatory affairs and clinical development,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “We are off to a strong start in 2024, marked by dosing the first patient in the phase 1/2 clinical trial for TNG348, receiving Orphan Drug Designation from the U.S. FDA for TNG462 and strengthening our cash position
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in March.Leerink Partners 2024 Global Biopharma ConferenceDate: Tuesday, March 12, 2024Time: 3:00 PM ETLocation: Miami, FLBarclays 26th Annual Global Healthcare ConferenceDate: Wednesday, March 13, 2024Time: 9:30 AM ETLocation: Miami, FLA live webcast of the presentations will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcasts will be archived on the Company's website for 90 days following the presentation.About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts.Abstracts accepted for poster presentationTitle: MTA-cooperative PRMT5 inhibitors selectively modulate RNA splicing in MTAP-deleted cancer cells across histologies. Poster #: B018. Presenter: Matthew R. Tonini, Senior Scientist, Tango Therapeutics
STOCKHOLM, Sept. 11, 2023 /PRNewswire/ -- Medivir AB(NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's partner Tango Therapeutics has received FDA clearance on its Investigational New Drug application for TNG348.TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers. HRD+ cancers, including BRCA1/2 mutations, represent up to 50% of ovarian cancers, 25% of breast cancers, 10% of prostate cancers and 5% of pancreatic cancers.Tango Therapeutics intends to initiate a phase 1 / 2 study with TNG348 in first half of 2024, both as single agent and in combination with a PARP-inhibitor. Preclinical data has shown synergistic effect with PARP inhibitors in PARP naïve models and that TNG348 is active in models with resistance to PARP inhibitors. These data suggest that TNG348 may benefit patients both as single agent or in combination with PARP inhibitors.TNG348 is a USP-1 inhibitor developed from the preclinical USP-1 program in-licensed from Medivir in 2020.Under the licensing agreement, Medivir is entitled to multiple development and commercial milestone payments as well as royalties on future sales."It is very encouraging to see another preclinical molecule developed by Medivir being evaluated in patients. The preclinical data generated by Tango Therapeutics looks very promising and we will be following the clinical development of TNG348 with great anticipation," says Jens Lindberg, CEO of Medivir.For additional information, please contact;Magnus Christensen, CFO, Medivir ABTelephone: +46 8 5468 3100